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Abstract 
Streptococcus equi ssp. zooepidemicus (S. equi spp. zooepidemicus) is an opportunistic pathogen that causes major 
economic losses in the swine industry in China and is also a threat for human health. Biofilm formation by this bacte‑
rium has been previously reported. In this study, we used an immunoproteomic approach to search for immunogenic 
proteins expressed by biofilm‑grown S. equi spp. zooepidemicus. Seventeen immunoreactive proteins were found, of 
which nine common immunoreactive proteins were identified in planktonic and biofilm‑grown bacteria. The immu‑
nogenicity and protective efficacy of the S. equi spp. zooepidemicus immunoreactive GroEL chaperone protein was 
further investigated in mice. The protein was expressed in vivo and elicited high antibody titers following S. equi spp. 
zooepidemicus infections of mice. An animal challenge experiment with S. equi spp. zooepidemicus showed that 75% 
of mice immunized with the GroEL protein were protected. Using in vitro biofilm inhibition assays, evidence was 
obtained that the chaperonin GroEL may represent a promising target for the prevention and treatment of persistent 
S. equi spp. zooepidemicus biofilm infections. In summary, our results suggest that the recombinant GroEL protein, 
which is involved in biofilm formation, may efficiently stimulate an immune response, which protects against S. equi 
spp. zooepidemicus infections. It may therefore be a candidate of interest to be included in vaccines against S. equi 
spp. zooepidemicus infections.
© 2016 Yi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Streptococcus equi ssp. zooepidemicus (S. equi spp. 
zooepidemicus) is an opportunistic pathogen that 
causes important economic losses in the swine industry 
in China and is also a threat for human health [1]. It is 
indeed a major problem in China and the development 
of an effective vaccine is vital to circumvent the signifi-
cant economic impact to the industry. Previous stud-
ies have investigated different immunogenic proteins of 
planktonically grown S. equi spp. zooepidemicus, includ-
ing secreted and surface-associated proteins [2–4]. Mao 
et  al. [3, 4] used the immunoproteomic technology to 
study the convalescent serum of mini-pigs and identified 
12 membrane-associated proteins, 13 cell wall-associated 
proteins, and seven extracellular proteins in S. equi spp. 
zooepidemicus. Based on enzymatic shaving and Western 
blot analyses, Wei et  al. [2] described five novel mem-
brane-associated vaccine candidate proteins.
We recently reported that S. equi spp. zooepidemicus 
can form biofilms [5]. Given that bacteria within biofilms 
have an increased resistance to the host defence system 
and antibiotics, infections caused by biofilm-producing 
bacteria are frequently chronic, recurrent, and resistant 
to antibacterial chemotherapy [6]. Immunoprophylaxis 
and immunotherapy targeting biofilm-related proteins 
are promising new approaches for the prevention and 
treatment of biofilm-associated infections [7]. The immu-
noproteomic technology has been successfully used to 
identify relevant bacterial antigens for the development 
Open Access
*Correspondence:  fhj@njau.edu.cn 
1 Key Lab of Animal Bacteriology, Ministry of Agriculture, Nanjing 
Agricultural University, Nanjing, China
Full list of author information is available at the end of the article
Page 2 of 9Yi et al. Vet Res  (2016) 47:50 
of new vaccines [8, 9]. This technique might also be use-
ful to increase our understanding of the molecular mech-
anisms that control biofilm formation by S. equi spp. 
zooepidemicus.
In the present study, immunogenic proteins expressed 
by biofilm-grown S. equi spp. zooepidemicus were iden-
tified using an immunoproteomic approach. The chaper-
onin GroEL was found to be an immunogenic protein in 
both biofilm- and planktonic-grown S. equi spp. zooepi-
demicus. The immunogenicity of the recombinant GroEL 
protein, the protection rate of GroEL-immunized mice, 
and the capacity of anti-GroEL antibodies to inhibit bio-




All the animal experiments were performed with the 
approval of the Laboratory Animal Monitoring Com-
mittee of Jiangsu Province (SYXK (SU) 2011-0036). All 
efforts were made to minimize animal suffering and to 
reduce the number of animals used.
Bacteria and culture conditions
Streptococcus equi ssp. zooepidemicus strain ATCC 35246 
was initially isolated from a diseased pig in Sichuan Prov-
ince, China, in 1976. The strain, which was purchased 
from the American Type Culture Collection (ATCC), 
was cultured in Todd-Hewitt broth (THB, Oxoid) and on 
THB agar plates. Biofilms of S. equi spp. zooepidemicus 
were prepared by growing bacteria in THB medium sup-
plemented with 1% human fibrinogen (Sigma) in polysty-
rene Petri dishes at 37 °C for 24 h, as described previously 
[5]. Quantification of biofilm production was carried out 
by a microtiter plate assay using crystal violet staining. S. 
equi spp. zooepidemicus planktonic cells grown at 37  °C 
for 24  h in Erlenmeyer flasks containing the above cul-
ture medium were used as the control.
Whole cell protein sample extraction
Bacterial proteins were prepared as described previously 
[5, 10]. Briefly, following biofilm formation, the medium 
containing free-floating bacteria was poured off, and the 
wells were washed three times with sterile PBS to remove 
loosely attached bacteria. The biofilms were detached by 
scraping, were suspended in 50 mM Tris-HC1 (pH 7.5), 
and were sonicated for 5  min. The sonicated biofilms 
were pelleted by centrifugation at 8000 × g for 5 min at 
4 °C. The pellets were washed twice in 50 mM Tris-HC1 
(pH 7.5) and were then resuspended in buffer (50  mM 
Tris–HCl, pH 7.5, 3  mM MgCl2, 50% sucrose) contain-
ing 1000 U/mL of mutanolysin (Sigma) and were incu-
bated for 90  min at 37  °C. Spheroplasts were collected 
and were resuspended by sonication on ice (100  W, 
90 cycles, 5 s on and 10 s off) in sonication buffer (7 M 
urea, 2  M thiourea, 4% 3-[(3-cholamidopropyl) dimeth-
ylammonio]-1- propanesulfonate (CHAPS), and 65  mM 
dithiothreitol (DTT,GE Healthcare). Spheroplasts were 
then incubated at 25 °C for 30 min, following which cell 
debris and unbroken cells were removed by centrifuga-
tion at 10 000 × g for 30 min at 25 °C. The supernatants 
were mixed with 10% Trichloroacetic acid (TCA) and 
were incubated in ice water for 30 min. The precipitated 
proteins were pelleted by centrifugation at 10 000 × g for 
10  min at 4  °C and were washed twice with pre-chilled 
acetone. The final pellet was air-dried, dissolved in sam-
ple preparation solution (7  M urea, 2  M thiourea, 4% 
CHAPS, 65  mM DTT), incubated for 30  min at 25  °C 
(vortexed every 10  min), and centrifuged at 10  000 ×  g 
for 20  min at 25  °C. Prior to rehydration, the superna-
tants were treated with 2-D Clean-up kits (GE Health-
care) to remove contaminants that may interfere with 
the electrophoresis. The protein content was determined 
using PlusOne 2-D Quant kits (GE Healthcare).
2‑D gel electrophoresis
The 2-DE (two-dimensional gel electrophoresis) was 
performed using the immobiline/polyacrylamide sys-
tem. The isoelectric focusing (IEF) was performed using 
IPG DryStrips (13 cm; IPGphor; GE Healthcare). Protein 
samples (200 μg) were applied to the IPG strips using the 
in-gel sample rehydration technique according to the 
manufacturer’s instructions. The IEF was performed in 
a protein IEF cell (GE Healthcare) using a stepwise volt-
age gradient to 80 kVh. The strips were equilibrated for 
2 ×  15  min in equilibration buffer (6  M urea, 2% SDS, 
30% glycerol, 50  mM Tris–HCl, pH 8.8) supplemented 
with 1% DTT and 4% iodoacetamide prior to running the 
second dimension. The SDS-PAGE was carried out verti-
cally on 12.5% polyacrylamide gels using an Ettan DALT 
II system (GE Healthcare). Resolved proteins were rou-
tinely stained with Coomassie Brilliant Blue G-250 for 
protein identification purposes. All experiments were 
performed in triplicate. The reproducibility of the 2-DE 
was verified by running the same samples at least three 
times on separate gels. Three replicate gels from three 
independent experiments were run for each growth con-
dition. The gels were compared using Image Master Plati-
num 5.0 software (GE Healthcare).
Preparation of convalescent sera
The pathogen-free mini-pigs used in this study had no 
history of S. equi spp. zooepidemicus infection and were 
found to be negative for antibodies against S. equi spp. 
zooepidemicus ATCC 35246 whole cells, as determined 
by an enzyme-linked immunosorbent assay (ELISA). 
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Swine convalescent sera were obtained from the pigs 
artificially infected with live S. equi spp. zooepidemicus 
ATCC 35246. Pre-infection sera were used as a negative 
control. The protocol of Zhang and Lu [11] was used for 
the immunization procedure and immunogen prepara-
tion. Pigs were intramuscularly injected twice at 3-week 
interval with 1.0 × 109 CFU (Colony-Forming Units) of 
S. equi spp. zooepidemicus. Swine sera were collected 
7  days after the booster injection, and serum IgG anti-
body titers were determined using a whole cell ELISA [3]. 
Wells of the microplate were coated with formaldehyde-
inactive S. equi spp. zooepidemicus (1.0 × 106 cells), and 
blocked with 5% skim milk. Two-fold serial dilutions 
(from 1:500 to 1:16 000) of the sera were added and the 
plate was incubated for 2 h. Following incubation in the 
presence of horseradish peroxidase (HRP)-conjugated 
goat anti-mouse IgG as the secondary antibody, the 
color was developed by adding 3,3′,5,5′-tetramethylb-
enzidine (TMB) substrate (Beyotime Institute, China). 
Color development was recorded by reading the absorb-
ance of 450 nm using a microtiter plate reader (Bio-Rad, 
USA). Sera with high titers were selected for subsequent 
experiments.
Western blotting
Protein samples from each SDS-PAGE gel were trans-
ferred onto polyvinylidene difluoride (PVDF) membranes 
(GE Healthcare) using a semi-dry blotting apparatus 
(TE77, GE Healthcare) for 2  h at 0.65  mA/cm2. After 
the transfer, membranes were blocked by incubation 
for 2 h in 100 mM Tris–HCl, 150 mM NaCl, and 0.05% 
Tween-20 (TBST) containing 5% skim milk. The blocked 
membranes were incubated with sera from convales-
cent mini-pigs (1:1000 dilution) for 2  h at room tem-
perature with gentle agitation. They were then washed 
three times with TBST (10  min per wash) and were 
incubated (1  h with gentle agitation) with horseradish 
peroxidase-labeled Staphylococcal protein A (Boster, 
China) at a dilution of 1:5000 in blocking solution. The 
membranes were washed as before, and were incubated 
with 3,3′-diaminobenzidine (Tiangen, China) until the 
optimum color was obtained. This analysis was repeated 
three times for each sample.
Mass spectrometric analysis of protein spots and database 
searches
The Coomassie Brilliant Blue-stained spots correspond-
ing to the immunoreactive proteins were excised from 
the 2-D gels and were sent to Shanghai Applied Pro-
tein Technology Co. Ltd for tryptic in-gel digestion, 
Matrix-Assisted Laser Desorption/Ionization Time of 
Flight Mass Spectrometry (MALDI-TOF–MS), and 
MALDI-TOF/TOF–MS. The MALDI-TOF–MS and 
MALDI-TOF/TOF–MS acquisition data were used in a 
combined search against the NCBInr protein database 
using MASCOT (Matrix Science), with parameter sets 
for trypsin digestion, one max missed cleavage, variable 
modification of oxidation (M), and a peptide mass toler-
ance for monoisotopic data of 100  ppm. The MASCOT 
server was originally used to search the NCBInr for 
peptide mass fingerprinting (PMF). The criteria used to 
accept protein identifications were based on PMF data, 
including the extent of sequence coverage, the number 
of peptides matched, and the score of probability. Protein 
identification was assigned when the following criteria 
were met: at least four matching peptides and sequence 
coverage greater than 15%.
Confirmation of the immunogenicity of selected proteins
The GroEL chaperone protein was selected for molecu-
lar cloning and its immunogenicity was confirmed. 
The primer pairs of GroEL-S (5′-CGCGAATTCGATA 
TTTTGGCGGATACCGT-3′) and GroEL-A (5′-CC 
CTCGAGAGCAGGCTCTGGCTTAGTGG-3′) were 
designed to express the recombinant protein based on 
the gi number (Table  1). More specifically, GroEL PCR 
product was cloned into the pET28a expression vec-
tor as described in a previous study [12]. The resulting 
plasmid was used to transform Escherichia coli DH5α. 
(TaKaRa, China). Expression of the recombinant pro-
tein was induced in E. coli BL21(DE3) (TaKaRa, China) 
at 37  °C for 4  h with 0.1  mM IPTG (Isopropyl β-d-
Thiogalactoside). The protein was purified by HisTrap FF 
column (GE Healthcare, USA) and purity was analyzed 
by SDS-PAGE [13]. The immunogenicity of the GroEL 
protein was confirmed by Western blot analysis using pig 
convalescent sera directed against the S. equi spp. zooepi-
demicus ATCC 35246 strain.
Mouse vaccination and determination of protection 
efficacy
Thirty-two ICR (Institute of Cancer Research) mice 
(4-week-old females) were randomly assigned to four 
groups of eight mice each. The mice in Group 1 were 
intramuscularly injected with 0.2  mL of recombinant 
GroEL protein (rGroEL; 100  µg/mL) mixed with an 
equivalent volume of MONTANIDE ISA 206 VG (SEP-
PIC, France). The mice in Group 2 were intramuscularly 
injected with 0.2 mL of formaldehyde-inactivated S. equi 
spp. zooepidemicus ATCC35246 vaccine (1 × 109 cfu/mL) 
combined with MONTANIDE ISA 206 VG and served 
as positive controls. The second booster from groups 
1 and 2 were intramuscularly injected with the recom-
binant GroEL protein and whole-cell vaccine at day 14, 
respectively. The mice in group 3 were intramuscularly 
injected with PBS and served as negative controls. The 
Page 4 of 9Yi et al. Vet Res  (2016) 47:50 
mice in Group 4 served as blank controls. One hundred 
μL of orbit blood were collected from each mouse. The 
blood samples used to prepare the sera were obtained 
on days 0, 7, 14, 24, and 28. Three mice from each group 
were sampled at random on each date. Blood were clot-
ted and sera were prepared by centrifugation and were 
stored at −20 °C for later analysis. To measure serum IgG 
antibody, all titers of sera were evaluated using indirect 
ELISA.
Two weeks after the second booster dose, the mice 
in groups 1–3 were inoculated intraperitoneally with 
0.2  mL of bacterial suspensions (1.25  ×  106 cfu/mL, 
approximately 5 × LD50) obtained from an 18-h culture 
in THB to evaluate the protection against an S. equi spp. 
Table 1 Immunoproteins identified by MALDI-TOF/TOF MS
a gi number in NCBI.
b Theoretical MW and pI was calculated using compute pI/MW [38].
c MASCOT score obtained for the peptide mass fingerprint (PMF). The significance threshold was 70.
d Number of peptides that match the predicted protein sequence.
e Percentage of predicted protein sequence covered by matched peptides.










MASCOT score c No. of peptides 
matched d
Coverage (%)e
BF1 gi|338846659 DNA polymerase III 
delta subunit
39 994/5.80 22 000/5.70 252 19 55
BF2 gi|195977415 elongation factor G 76 540/4.83 76 000/4.80 232 20 40
BF3 gi|195978009 pyruvate kinase 54 638/5.09 55 000/5.10 374 36 62
BF4 gi|338847723 Transketolase 71 341/5.07 71 000/5.09 272 11 21
BF5 gi|338846410 chaperone protein 
DnaK (heat shock 
protein 70)
65 045/4.64 60 000/4.60 269 22 36
BF6 gi|225867742 60 kDa chaperonin 
GroEL
56 876/4.70 56 000/4.60 575 34 60
BF7 gi|195978262 30S ribosomal 
protein S1








43 738/5.44 40 000/5.40 164 17 52
BF10 gi|338847987 adenylosuccinate 
synthetase
47 501/5.47 47 000/5.60 155 18 49
BF11 gi|225869251 phosphoglycerate 
kinase
42 184/4.96 42 000/4.90 120 14 38
BF12 gi|225867788 glucose‑6‑phos‑
phate isomerase




37 025/5.57 40 000/5.00 243 24 58
BF14 gi|338846346 pyridine nucleo‑
tide‑disulfide 
oxidoreductase
47 715/5.30 47 000/5.30 191 21 56






72 742/5.56 72 000/5.60 244 25 49
BF16 gi|338847405 Elongation factor‑
Tu
44 545/4.89 21 000/5.30 109 9 22
BF17 gi|225867729 elongation factor 
Ts
37 263/4.86 30 000/4.40 193 20 59
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zooepidemicus challenge [14, 15]. Another eight mice in 
Group 4 were injected with 0.2 mL of sterile PBS.
The effect of anti‑rGroEL antibodies on biofilm formation 
by S. equi spp. zooepidemicus
The biofilm assay was performed as described by Zarank-
iewicz et  al. [16], with modifications. A S. equi spp. 
zooepidemicus colony was inoculated into 5 mL of THB 
and was cultivated with shaking at 37  °C for 12  h (late 
exponential/stationary growth phase) [15]. The culture 
was diluted 1:100 with fresh THB broth supplemented 
with 1% fibrinogen and with either 1% pooled mouse 
anti-rGroEL serum or 1% pooled non-immunized mouse 
sera from day 35. After a 2 h incubation at 4 °C, 200 µL 
of the mixtures (106 cell per well) was added to each well 
of a 96-well polystyrene microtiter plate. The plate was 
incubated at 37  °C for 24  h without shaking. A S. equi 
spp. zooepidemicus culture in THB medium containing 
1% fibrinogen was used for the positive control. Uninocu-
lated culture medium containing 1% fibrinogen was used 
for the negative control. Biofilms were quantified by crys-
tal violet staining as described by Wang et  al. [17]. The 
medium containing free-floating bacteria was poured off 
and the wells were washed three times with sterile PBS. 
Microtiter plate wells were then stained with 200  µL of 
1% (w/v) crystal violet for 10 min and washed four times 
with PBS to remove unbound crystal violet dye, and then 
air dried for 1 h. Biofilm-adsorbed crystal violet was reso-
lubilized by adding 200 µL 95% (v/v) ethanol of each well, 
and the absorbance was measured at 595  nm. All the 
assays were performed in triplicate.
Statistical analysis
Statistical analyses were carried out using the GraphPad 
Software package. Survival data were assessed by Kaplan 
C Meier survival analysis and tested for significance by 
the log rank test. Other data were analyzed using the 




A 2-DE covering a pH range of 4–7 (IPG linear gradient) 
was performed to separate whole cell proteins prepared 
from biofilm-grown S. equi spp. zooepidemicus. The spots 
were detected by Coomassie Brilliant Blue G-250 stain-
ing (Figure  1A). Western blotting with pig convalescent 
sera revealed the presence of seventeen immunoreac-
tive proteins in the biofilm-grown bacterial samples 
(Figure 1B), which was consistent with our observations 
of the duplicated 2-D gel (Figure  1A). The seventeen 
spots were excised and were characterized by MALDI-
TOF–MS and MALDI-TOF-TOF–MS, and the data 
were compared to those in the NCBI sequence database. 
The probability score for the match, MW, pI, and num-
ber of peptide matches were used to identify the spots. 
The seventeen immunoreactive spots, listed in Table  1, 
corresponded to seventeen different proteins. Nine of 
these immunoreactive proteins were also identified in 
planktonic-grown bacteria using the same protocol [4]: 
a DNA polymerase III delta subunit, elongation factor 
G, pyruvate kinase, transketolase, the GroEL molecular 
chaperone, glyceraldehyde-3-phosphate dehydrogenase, 
pyridine nucleotide-disulfide oxidoreductase, oligopep-
tide ABC transporter periplasmic oligopeptide-binding 
protein OppA, and elongation factor Ts. Since the GroEL 
molecular chaperone is essential for biofilm formation in 
other bacteria [18], it was selected for further analysis.
Western blot analysis of the recombinant proteins
The GroEL protein of S. equi spp. zooepidemicus was 
cloned in E. coli. The immunogenicity of the rGroEL pro-
tein was confirmed by Western blotting using mini-pig 
convalescent sera (Figure 2).
Antibody response to vaccination with the rGroEL protein
The GroEL-specific antibody response elicited by immu-
nization with the rGroEL protein was monitored by 
determining the serum antibody titers of all the experi-
mental mice. The GroEL protein-specific antibody titers 
of mice vaccinated with the recombinant protein were 
markedly higher than those of the PBS-injected mice at 
day 7 post-vaccination and continued to increase by day 
28 (Figure 3). The antibody titers of the rGroEL protein-
vaccinated mice were significantly higher (P < 0.01) than 
those of the PBS-injected mice at all time points post-
vaccination. No significant differences in titers were 
found between the rGroEL protein-vaccine and the inac-
tivated S. equi spp. zooepidemicus vaccine (P > 0.05).
Immunoprotection provided by the rGroEL vaccine in mice
Immunized and non-immunized mice were monitored 
daily for 7  days following a challenge with S. equi spp. 
zooepidemicus. In the non-immunized group, the first 
death of mice occurred 24 h after the challenge, and the 
mortality rate reached 100% within 48  h. In the groups 
immunized with rGroEL or the inactivated bacterial vac-
cine, only 2 out of 8 mice (25%) died following the chal-
lenge with S. equi spp. zooepidemicus. More specifically, 
the deaths occurred at day 3 post-injection. The immu-
noprotection rate for these two groups was 75% in both 
cases (Figure  4). Compared with the non-immunized 
group,the mice in the groups immunized with rGroEL 
or the inactivated S. equi spp. zooepidemicus vaccine 
had higher survival rates (P  <  0.05). No significant dif-
ferences in survival rates were found between the group 
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immunized with rGroEL and the group inactivated S. 
equi spp. zooepidemicus vaccine (P > 0.05).
Biofilm inhibition by the anti‑rGroEL antibody in vitro
Biofilm formation by S. equi spp. zooepidemicus was 
assessed in a microplate assay and crystal violet stain-
ing. Biofilm formation by S. equi spp. zooepidemicus cul-
tured in THB medium supplemented with anti-rGroEL 
serum (0.32  ±  0.06) was significantly lower (P  <  0.01) 
than that of S. equi spp. zooepidemicus cultured in THB 
medium alone (1.11  ±  0.05) or in THB medium sup-
plemented with non-immunized pathogen-free mouse 
serum (0.96 ± 0.10). No significant differences in A595 nm 
were found between S. equi spp. zooepidemicus cultured 
in THB medium alone and S. equi spp. zooepidemi-
cus cultured in the THB medium supplemented with 
non-immunized mouse serum (P  >  0.05). These results 
Figure 1 2-D gel electrophoresis profiles of whole cell lysates of biofilm-grown S. equi spp. zooepidemicus with the immunoreactive 
proteins indicated. A Protein staining with Coomassie B‑250. B Western blot analysis of the immunoreactive proteins using pig convalescent 
serum. Immunoreactive spots are indicated by the abbreviation of biofilm (BF) followed by an arbitrary number.
Figure 2 SDS-PAGE and Western immunoblotting analysis of 
the rGroEL protein expressed in E. coli BL21. Lane M, protein 
molecular mass marker; lane 1, Western blot analysis of puried rGroEL 
protein using pre‑immune mini‑pig sera as the negative control; 
lane 2, Western blot analysis of puried rGroEL protein using mini‑pig 
convalescent sera; lane 3, the elution of the purified rGroEL were 
separated on an SDS‑PAGE and stained with coomassie; lane 4, rGroEL 
protein in E. coli BL21induced with 1 mM IPTG for 4 h; lane 5, rGroEL 
protein without IPTG; lane 6, empty expression vector pET28a (+).
Figure 3 Antibody response following vaccination. Three mice 
from each group were sampled at random on each date. Data rep‑
resent the mean ± standard deviation (n = 3 per group) of antibody 
titers (log 10) vs. days post‑vaccination. Bars indicate standard devia‑
tions. The antibody titers of the rGroEL protein‑vaccinated mice were 
significantly higher (P < 0.01) than those of the PBS‑injected mice at 
all time points post‑vaccination. No significant differences in titers 
were found between the rGroEL protein‑vaccine and the inactivated 
S. equi spp. zooepidemicus vaccine (P > 0.05).
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suggest that other components found in blood serum had 
no inhibitory effect on S. equi spp. zooepidemicus growth 
or biofilm production and that the anti-rGroEL antibody 
had an inhibitory effect on biofilm production (Figure 5).
Discussion
S. equi spp. zooepidemicus is associated with a wide 
variety of infections in many animal species, including 
horses, cows, swine, sheep, and dogs [19]. More spe-
cifically, S. equi spp. zooepidemicus is the main bacterial 
swine pathogen in China [1]. It could also be detected in 
pigs without apparent clinical signs or symptoms of infec-
tion. It has also been reported to cause zoonotic infec-
tions in humans [20]. The disease is generally sporadic 
and outbreaks are usually of short duration; however in 
large herds the bacteria may be present for longer periods 
[21–24]. Previous studies have shown that S. equi spp. 
zooepidemicus can be isolated from previously described 
outbreaks in pig herds, thus suggesting that some S. equi 
spp. zooepidemicus strains can form dormant or persister 
cells that can be reactivated and cause infections [23, 25].
In other bacterial species, biofilms have been shown 
to play a key role in causing chronic infections [26, 27]. 
Grenier et  al. [28] reported that a Streptococcus suis 
serotype 2 strain isolated from a case of meningitis in 
pigs could form a dense biofilm and suggested a correla-
tion between biofilm formation and the establishment of 
infection. Bacteria with a capacity to colonize the host by 
forming biofilms have significant advantages in establish-
ing persistent infections [29]. S. equi spp. zooepidemicus 
has been previously reported to form biofilms; differ-
ences in gene expression and protein profiles for plank-
tonic- and biofilm-grown bacteria were demonstrated [5]. 
Attempts to efficiently control S. equi spp. zooepidemi-
cus infections are complicated due to a lack of thorough 
knowledge on protective bacterial antigens. Therefore, it 
is important to identify antigenic components of inter-
est for the development of a potential vaccine candidate 
against S. equi spp. zooepidemicus infections.
In this study, we used an immunoproteomic approach 
to search for immunoreactive S. equi spp. zooepidemi-
cus proteins in biofilms. While previous studies have 
assessed the immunogenicity of S. equi spp. zooepidemi-
cus using planktonic cells [3, 4], our report is the first 
to describe biofilm-specific proteins recognized by host 
antibodies. We identified seventeen immunoreactive 
proteins, of which nine were present in both planktonic 
and biofilm-grown bacteria. To our knowledge, this is 
the first time that the other eight immunoreactive pro-
teins have been described in S. equi spp. zooepidemicus. 
The common immunoreactive proteins may be promis-
ing candidates for the development of a vaccine aimed at 
preventing both biofilm formation and acute S. equi spp. 
zooepidemicus infections. In this regard, the GroEL pro-
tein may be of high interest.
GroEL belongs to the chaperonin family of molecular 
chaperones. It is essential for biofilm formation in the 
Gram negative actinobacterium Haemophilus influen-
zae [18]. GroEL in Streptococcus pneumoniae can induce 
high antibody titers, promote lymphocyte proliferation, 
and induce both humoral and cell-mediated immune 
Figure 4 Protective efficacy by vaccination in mice. Mice were 
injected with S. equi spp. zooepidemicus ATCC35246 and mortality was 
recorded daily for 7 days. Mice in the non‑immunized group died 24 
to 48 h after the challenge, and the mortality rate reached 100%. Mice 
in the groups immunized with rGroEL or the inactivated S. equi spp. 
zooepidemicus vaccine died 48 to 72 h after the challenge with S. equi 
spp. zooepidemicus and 75% survived 7 days post‑infection for these 
two groups. Significant differences in survival were noted, log rank 
test, P < 0.05. Compared with the non‑immunized group, the mice 
in the groups immunized with rGroEL or the inactivated S. equi spp. 
zooepidemicus vaccine had higher survival rates (P < 0.05).
Figure 5 Quantitative microtiter plate assay for biofilm 
production by S. equi spp. zooepidemicus. Biofilm formation was 
evaluated by monitoring the A595 nm following crystal violet staining 
of bacterial cultures. The columns represent the means and standard 
deviations of three experiments. A Biofilm formation in THB medium 
(control); B Biofilm formation in THB medium supplemented with 
normal mouse serum; C Biofilm formation in THB medium supple‑
mented with mouse rGroEL‑antiserum; D THB medium. Student’s 
t‑test was performed for the statistical significance analysis. Biofilm 
formation in THB medium supplemented with anti‑rGroEL serum (C) 
was significantly lower (P < 0.01) than that of S. equi spp. zooepidemi-
cus cultured in THB medium alone (A) or in THB medium supple‑
mented with non‑immunized pathogen‑free mouse serum (B). No 
significant differences were found between S. equi spp. zooepidemi-
cus cultured in THB medium alone and S. equi spp. zooepidemicus 
cultured in the THB medium supplemented with non‑immunized 
mouse serum (P > 0.05).
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responses, suggesting that it may represent a protein of 
therapeutic interest [30]. A number of immunoprot-
eomic studies have shown that GroEL is an immunogenic 
protein in a wide variety of bacteria, including Helicobac-
ter pylori, Riemerella anatipestifer, Brucella spp., and E. 
coli [31–36]. Immunization with GroEL has also been 
shown to induce protection in a number of infection 
models. For instance, a significantly higher antibody titer 
was produced when mice were immunized with GroEL 
from Streptococcus pneumoniae, providing 50% protec-
tion rate against lethal infections [30]. In BALB/c mice, 
passive immunization with GroEL from Bacillus anthra-
cis conferred 100% protection against Bacillus anthracis 
infections [37].
A mouse model was used to investigate the immuno-
genicity and protective immune response of the recom-
binant S. equi spp. zooepidemicus GroEL protein. Based 
on the ELISA results, the protein elicited high antibody 
titers. Animal challenge experiments with the S. equi spp. 
zooepidemicus ATCC35246 strain showed that 75% of the 
immunized mice were protected, a protection rate com-
parable to that obtained with inactivated bacterins.
GroEL is present in several bacterial fractions, includ-
ing the cytosol, cell membrane, and extracellular material 
[38]. It is also the compound in the biofilm supernatant 
that is responsible for the anti-inflammatory effect of 
suppressing TNF-α production in Lactobacilli [39]. The 
GroEL of S. equi spp. zooepidemicus appeared to be 
involved in the production of biofilm since the presence 
of anti-rGroEL antibodies in the culture medium inhib-
ited biofilm formation. The GroEL may thus be a prom-
ising target for the prevention/treatment of S. equi spp. 
zooepidemicus biofilm-related infections. Similar results 
with antibody-mediated strategies to prevent biofilm 
formation have been published previously. Zarankie-
wicz et al. [16] reported that the presence of anti-rHsp60 
(GroEL) antibodies in BHI broth medium inhibited 
biofilm production by Histophilus somni in  vitro. They 
observed small biofilm particles in the presence of the 
anti-rHsp60 antibody, whereas large biofilm complexes 
were produced in the control cultures.
In conclusion, the present study identified immuno-
reactive proteins in S. equi spp. zooepidemicus grown in 
biofilms for the first time. It also brought strong evidence 
that the rGroEL protein is a promising candidate for the 
development of vaccines against S. equi spp. zooepidemi-
cus infections.
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